Fig. 3
Mean changes in body mass following Elexacaftor/Tezacaftor/Ivacaftor therapy in patients with cystic fibrosis, according to sex (panel a), age category (panel b), residual function mutation (panel c), pancreatic insufficiency (panel d), chronic respiratory infection by P. aeruginosa (panel e), cystic fibrosis related diabetes (panel f), respiratory function (panel g) and body mass index (panel h). Mean changes were estimated using mixed effects regression models including subject-specific random intercepts and fixed effects for the predictor variable, time and a predictor-by-time interaction term. P-values indicate the statistical significance of the interaction term: i.e. differences in treatment response across levels of the predictor. R2 indicates the proportion of the variance in BMI changes explained by the fixed effect terms
BMI: body mass index. CFRD: cystic-fibrosis related diabetes. ETI: Elexacaftor/Tezacaftor/Ivacaftor. Pa: Pseudomonas aeruginosa. PI: pancreatic insufficiency. ppFEV1: percent of predicted forced expiratory volume in one second. RFM: Residual function mutation